Lumexa Imaging (LMRI) Q4 2025 earnings review
Strong Outpatient Volumes Driven by IPO Transition, but Growth Slower Ahead
Lumexa Imaging closed out 2025 with solid top-line performance. Consolidated revenues grew 7.9% in Q4, and the company successfully reduced its leverage from 5.5x to 3.5x following its IPO, yielding an expected $50M in annual cash savings. However, while Adjusted EBITDA surged 18.6% in the quarter, the GAAP net loss widened to $28.7M due to one-time debt extinguishment and transaction costs. Looking forward, management's FY26 guidance implies a clear deceleration in both revenue and adjusted earnings as new public company costs weigh on the bottom line.
🐂 Bull Case
The mix shift toward highly profitable advanced procedures (MRI and CT) is accelerating. Consolidated same-center advanced volume grew 12.7% in Q4, outpacing the 8.0% growth rate seen for the full year.
Following its IPO, Lumexa used proceeds to aggressively pay down $1.2B in long-term debt, refinancing to lower rates. This two-turn leverage reduction locks in approximately $50M in annual interest savings.
🐻 Bear Case
Despite a 14.6% increase in Adjusted EBITDA for the year, Net Cash Provided by Operating Activities plummeted 58% YoY (from $40.7M to $17.1M), driven heavily by unfavorable working capital shifts and IPO-related transaction costs.
FY26 guidance points to revenue growth slowing to roughly 4.7% at the midpoint, and Adjusted EBITDA growth cooling to 3.4% as the company absorbs roughly $7M in new public company overhead.
⚖️ Verdict: ⚪
Neutral. The operational turnaround (de novo expansions and advanced imaging mix) and the cleaner balance sheet are highly attractive. However, deteriorating cash flow metrics and cautious FY26 growth targets require investors to temper immediate expectations.
Key Themes
Advanced Imaging Volumes Accelerating
The operational star of Q4 was the shift to higher-margin advanced modalities. Consolidated advanced procedures jumped 14.2% YoY to 190,982. The penetration of advanced procedures as a percentage of total procedures expanded by 110 basis points to 30.4%. Management successfully captured the ongoing macro shift of patients from costly hospital settings to more efficient outpatient care.
Aggressive De Novo Strategy Executed
Lumexa opened a record 10 new imaging facilities in 2025 (9 de novo centers and 1 acquisition), setting the foundation for sustained same-center growth. Ramping these centers drove much of the top-line beat and gives clear visibility into future volume capacity.
Payer Network Restoration
Management specifically called out the return to in-network status with a large New Jersey payer as a catalyst for the strong Q4 volume bump. Restoring local network dynamics serves as an immediate, high-margin pipeline for local centers.
Operating Cash Flow Contradicts Profitability Claims
Management's narrative focuses heavily on the 14.6% jump in Adjusted EBITDA ($230.2M). However, hard cash generation tells a worsening story. Net cash from operating activities dropped violently from $40.7M in FY24 to just $17.1M in FY25. This 58% decline was driven by ballooning other receivables (-$12.6M hit), shrinking accrued expenses (-$17.9M hit), and elevated IPO-related transaction costs. Earnings quality appears challenged when cash conversion lags this substantially.
Elevated Non-Core Costs Obscuring Base Operations
The gap between GAAP and Non-GAAP metrics is widening significantly. In Q4 alone, the company booked $10.9M in M&A/Transaction costs (up from $4.1M a year ago) and another $13.4M loss on debt extinguishment. For the full year, adjustments for severance, strategic initiatives, and transaction costs eclipsed $28M. Investors must monitor when these 'one-time' costs will structurally normalize.
Stagnant Management Fee Revenues
While overall revenue grew solidly, the 'Management fee and other revenue' segment stalled in Q4, slipping slightly to $57.2M from $58.1M in the prior year. This signals potential pricing pressure or flat growth in the joint-venture management side of the business, forcing the company to rely exclusively on wholly-owned patient service revenues for total growth.
Other KPIs
Down 12.8% from $136.0M in FY24. This line item will shrink further in FY26. With the Q4 deleveraging event dropping the ratio to 3.5x, management expects an additional $50M in annual cash savings moving forward, shifting massive amounts of capital from debt servicing to potential free cash flow generation.
A massive improvement. Lumexa shaved over $366M off its long-term debt balance (which stood at $1.185B at the end of 2024), utilizing the $434.7M in net proceeds from its recent initial public offering.
Guidance
Decelerating. The midpoint of $1.071B implies a 4.7% YoY growth rate, which is a notable step down from the 7.8% growth achieved in FY25. This suggests the immediate boost from the New Jersey payer reinstatement and 2025 de novo openings will face tougher comps.
Decelerating. Midpoint represents 3.4% YoY growth, significantly cooling from the 14.6% expansion in FY25. Management notes this includes ~$7M in new public company compliance costs. Even adding that back, the underlying ~7% growth rate is half of what the company achieved this year.
Stable initiation of EPS guidance as a newly public entity. Represents a baseline target for profitability, though highly adjusted for ongoing M&A and restructuring activity.
Key Questions
Cash Flow Conversion Disconnect
Adjusted EBITDA grew nearly 15%, but operating cash flow dropped 58%. How much of the working capital drag in FY25 is permanent, and what is the expected cash flow conversion rate for FY26?
M&A vs Organic Growth Allocation
With leverage now comfortably at 3.5x, how will the company balance capital allocation between the proven de novo strategy and larger M&A targets in FY26?
Management Fee Stagnation
Q4 saw a slight YoY decline in management fee revenues. Are joint-venture partners pushing back on fee structures, or is this merely a timing issue with new JV center ramps?